Obese Clinical Trial - Effect of Increased Oxytocin Doses on the Mode of

Status Recruiting

Clinical Trial Summary

The rate of caesarean section is higher among obese pregnant women, leading to increased morbidity in this already vulnerable population. Oxytocin is the main drug used in obstetrics to optimize progress of labour, but observational studies have suggested that its efficiency may be insufficient in obese women with usual doses. We design a randomised controlled trial to test the effect of an increased oxytocin dose on the rate of caesarean section in obese primiparous women with spontaneous or induced labour.

Clinical Trial Description

The hypothesis underlying this trial is that an increase in oxytocin dose can reduce the rate of caesarean sections in primiparous obese patients, with a spontaneous or induced onset of labour, without increasing maternal or neonatal morbidity. This would be a major step forward in reducing morbidity in an at-risk population and in improving the obstetric prognosis for future pregnancies. The research is a double-blind controlled trial, including primiparous obese women in spontaneous or induced labour, for whom a prescription of oxytocin is decided. Oxytocin is currently indicated for notably "insufficiency of uterine contractions, at the beginning or during labour".The recommended dosage in the market authorization will be used for the control group. The control group will receive oxytocin at 2 milli-International unit /mL and the intervention group at 4 milli-International unit /mL, controlled by pump (final volume = 500 mL) or electrical syringe (final volume = 50 mL). The primary objective is to compare the effect of higher doses of oxytocin (intervention group) vs standard doses of oxytocin (control group) on the rate of caesarean sections in obese patients with spontaneous or induced onset of labour. The secondary objectives will be to compare the effect of higher doses of oxytocin (intervention group) vs standard doses of oxytocin (control group) on maternal and labour complications (length of labour, arrest of labour, interruption of oxytocin perfusion and reason, uterine hyper-stimulation, mode of vaginal delivery, reason for caesarean section, post-partum haemorrhage, maternal blood transfusion, volume of oxytocin infusion, oxytocin side effects), as well as foetal complications and neonatal complications. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04760496
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact	Alexandra BENACHI, PHD, MD
Phone	+33145374476
Email	alexandra.benachi@aphp.fr
Status	Recruiting
Phase	Phase 4
Start date	October 2, 2021
Completion date	November 2, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04105075` - COPD in Obese Patients
Completed	`NCT04099654` - The Effect of Core Stabilization Exercise Program in Obese Subjects Awaiting Bariatric Surgery	N/A
Recruiting	`NCT05857150` - Exercise Response in Humans With Obesity
Completed	`NCT03532672` - Early Effect of Fasting on Metabolic, Inflammatory, and Behavioral Responses in Females With and Without Obesity	N/A
Completed	`NCT02618486` - The Effects of Obesity on Non Surgical Periodontal Therapy	N/A
Completed	`NCT02086448` - Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)	N/A
Completed	`NCT01724515` - PGC-1 and Mitochondrial Dysfunction in Diabetes	N/A
Completed	`NCT01724502` - Mitochondrial Dysfunction in Diabetes	N/A
Active, not recruiting	`NCT01634204` - Efficacy of a Web-based Weight Loss Program	Phase 2
Completed	`NCT01479933` - Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes	N/A
Completed	`NCT01421589` - Growth Hormone Treatment on Phosphocreatine Recovery in Obesity	N/A
Completed	`NCT03528304` - Native Women's Wellness: Contingency Management for Tobacco Cessation and Weight Loss	N/A
Completed	`NCT01467817` - Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI)	N/A
Completed	`NCT01726647` - Metabolism Associated With Abdominal Fat Mass Distribution	N/A
Active, not recruiting	`NCT02125149` - The Expecting Study	N/A
Completed	`NCT05737927` - Pharmacodynamics and Pharmacokinetics of Different Glucose Bead Formulations in Obese Healthy Subjects	Phase 1
Completed	`NCT05433506` - Safety and Pharmacokinetics of HU6	Phase 1
Completed	`NCT02871882` - Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus	Phase 2
Completed	`NCT03298464` - Study of NGM313 in Obese Participants	Phase 1
Completed	`NCT05061173` - Comparison of Aerobic, Resistance, and Combined Training in Overweight/Obese Hypertensive Adults	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous or Induced Labour — PROXYMA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms